Gancotamab (MM-302) 是一种HER2靶向抗体-脂质体 Doxorubicin 偶联物，具有抗肿瘤活性。Gancotamab 封装 Doxorubicin 以促进其递送至 HER2 过表达肿瘤细胞。
| 生物活性 | Gancotamab (MM-302) is aHER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells[1]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Gancotamab (MM-302; 0.5 μM; 72 hours) increases cell death in BT474-M3 and NCI-N87 cells[1].
Gancotamab (MM-302; 1 μM; 2-24 h) activates the p-p53 level and has no effect on p-Akt signal in BT474-M3 and NCI-N87 cells[1].
Gancotamab (MM-302) is a HER2-targeted liposome encapsulating approximately 20,000 molecules of Doxorubicin in its core and 45 single-chain anti-HER2 antibodies (scFv) conjugated to its surface[1].
Cell Viability Assay[1] | Cell Line: | BT474-M3 and NCI-N87 cells | | Concentration: | 0.5 μM | | Incubation Time: | 72 hours | | Result: | Significantly reduced in vitro viability. |
Western Blot Analysis[1] | Cell Line: | BT474-M3 and NCI-N87 cells | | Concentration: | 1 μM | | Incubation Time: | 2 h, 8 h, and 24 h | | Result: | Increased the p-p53 level and had no effect on p-Akt signal. |
|
体内研究
(In Vivo) | Gancotamab (MM-302; 3 mg/kg; i.v.; every 7 days; for 3 doses) shows tumor growth inhibition and increases the expression of the DNA damage marker p-p53[1].
| Animal Model: | Seven-week-old female NCR/nu mice injected with NCI-N87 cells[1] | | Dosage: | 3 mg/kg | | Administration: | i.v.; every 7 days; for 3 doses | | Result: | Showed significantly antitumor activity. |
|
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com